pediatric primary enuresis. Nocturnal enuresis
Conditions
Interventions
Intervention 1: Intervention group 1: Solifenacin treated group (this group will be treated with Solifenacin 5 mg every night, manufactured by Caspin Daru Company, Rasht, Iran for 3 months. Then the p
Sponsors
Zahedan University of Medical Sciences
Eligibility
Sex/Gender
All
Age
5 Years to 14 Years
Inclusion criteria
Inclusion criteria: Children with primary enuresis referred to the clinic of Ali Bin Abi Talib Hospital in Zahedan Conscious consent to study Patient availability during quarterly follow-up Age 5 to 14 years
Exclusion criteria
Exclusion criteria: Structural disorders of the urinary tract Neurological bladder Psychiatric diseases Previous allergy to drugs History of taking medication (drug therapy) for enuresis Urinary incontinence
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Enuresis status (number of times). Timepoint: Before the intervention, one month and three months after the intervention. Method of measurement: Number of enuresis nights during 1 month.;Full recovery. Timepoint: 3 months after the intervention. Method of measurement: Based on the patient's history.;Complications during the intervention. Timepoint: During the 3 months of intervention. Method of measurement: Based on the patient's history.;Satisfaction with treatment. Timepoint: 3 months after the intervention. Method of measurement: Based on the 5-point criterion after taking the drug. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactFateme Ghaderi
Zahedan University of Medical Sciences
Outcome results
None listed